EYE informational update to YF vaccine manufacturers
Vaccination against YF is the single most important measure for YF prevention, with a single dose being capable of providing life-long immunity. Ensuring adequate vaccine supply for all at-risk populations remains critically important in the COVID-19 context. YF vaccines are currently manufactured by 4 WHO-prequalified suppliers (Bio-Manguinhos, Chumakov, Sanofi, Institut Pasteur Dakar) and through the EYE partnership, over a billion YF vaccine doses are expected to be delivered to countries with high YF risk by 2026. As part of its coordination role, the EYE programme management group (PMG) provides a quarterly informational update to the four global producers of the YF vaccine. During the most recent update in May, the EYE PMG highlighted the continued commitment to EYE at all levels despite COVID-19, the anticipated vaccination activities through 2022 and options for contingency plans if challenges to implement are encountered. This session provided an interactive forum with a clear representation of the actions being taken by the countries and by the partnership towards successful campaign planning and implementation, while acknowledging risks beyond the control of the partnership (political, insecurity, epidemic evolution) and options to mitigate any adverse impact.
|